What is the current Veterinary Infectious Diseases Therapeutics market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Veterinary Infectious Diseases Therapeutics market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Veterinary Infectious Diseases Therapeutics market?

Rising demand for pet healthcare and increasing prevalence of infectious diseases drive the market.

What are the major challenges facing the Veterinary Infectious Diseases Therapeutics market?

Antimicrobial resistance and high development costs are significant challenges.

Which regions are the leaders in the Veterinary Infectious Diseases Therapeutics market?

North America and Europe are the leading regions due to high pet ownership.

Who are the top companies in the Veterinary Infectious Diseases Therapeutics market?

Key players include Zoetis, Merck, and Elanco, offering a range of therapeutics.

What future opportunities exist in the Veterinary Infectious Diseases Therapeutics market?

Emerging markets and advancements in vaccine technology present opportunities.

How does technology impact the Veterinary Infectious Diseases Therapeutics market?

Advances in diagnostics and genomics improve disease management and treatment.

What is the regulatory landscape like for the Veterinary Infectious Diseases Therapeutics market?

Stringent regulations and approvals from authorities like FDA and EMA shape the market.

What is the future outlook for the Veterinary Infectious Diseases Therapeutics market?

The market is expected to grow significantly due to increasing demand for effective therapeutics.

Veterinary Infectious Diseases Therapeutics Growth Trends & Strategic Outlook 2033

Veterinary Infectious Diseases Therapeutics by Application (Swine, Chicken, Dog, Cat, Cow, Horse, Other), by Types (Antibiotics, Antiviral, Antifungal, Amebicides, Anthelmintics), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Veterinary Infectious Diseases Therapeutics Market Size | CAGR 7.8 Forecast 2033

Veterinary Infectious Diseases Therapeutics Growth Trends & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Veterinary Infectious Diseases Therapeutics Market Overview

The Veterinary Infectious Diseases Therapeutics market refers to the industry focused on developing and marketing treatments for infectious diseases in animals. As the veterinary healthcare sector continues to evolve, the Veterinary Infectious Diseases Therapeutics market size is estimated to be approximately $1.4 billion. The growth outlook for this market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033, driven by factors such as increasing awareness of animal health, advancements in veterinary medicine, and the rising demand for animal therapeutics. The industry expansion is expected to be shaped by key forces such as technology shifts, regulations, and consumer behavior.

Loading chart…

The largest region in the Veterinary Infectious Diseases Therapeutics market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing awareness of animal health and rising demand for veterinary care. Key forces shaping the industry include competitive intensity, supply-chain dynamics, and regulatory frameworks. As the market continues to evolve, players must stay ahead of the curve by investing in research and development, innovation, and strategic partnerships to capitalize on emerging opportunities and drive growth in the Veterinary Infectious Diseases Therapeutics market.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	21.88 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elanco Animal Health; Merck; Pfizer Animal Health; Boehringer Ingelheim Vetmedica; Virbac; Ceva Sante Animale; Novartis Animal Health; Dechra Animal Health; Sanofi
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Veterinary Infectious Diseases Therapeutics market is experiencing significant transformations, driven by various factors. The market dynamics are crucial in understanding the current and future trends in the industry.

Growth Drivers2 items

Increasing demand for pet health services and rising awareness about zoonotic diseases are driving the growth of the Veterinary Infectious Diseases Therapeutics market size. This trend is expected to continue, with a significant growth forecast in the coming years.

Advancements in vaccine technology and the development of novel therapeutics are also contributing to the market growth, enabling veterinarians to provide more effective treatments for infectious diseases in animals.

Restraints2 items

The high cost of research and development and the stringent regulatory requirements for the approval of new veterinary therapeutics are restraining the growth of the Veterinary Infectious Diseases Therapeutics market.

The availability of generic alternatives and the rising competition from alternative therapies are also limiting the market growth, making it essential for companies to develop innovative and cost-effective solutions.

Opportunities2 items

The increasing demand for companion animal health services in emerging markets presents significant opportunities for the Veterinary Infectious Diseases Therapeutics market to expand its global reach.

The growing focus on animal health and public health interface is creating new opportunities for the development of innovative therapeutics and diagnostics for infectious diseases in animals.

Challenges2 items

The rising concern about antimicrobial resistance and the need for sustainable use of antibiotics in veterinary medicine pose significant challenges for the Veterinary Infectious Diseases Therapeutics market.

The impact of global events, such as pandemics and economic downturns, on the supply chain and demand for veterinary therapeutics can also affect the market growth forecast, requiring companies to develop strategies to mitigate these risks.

Market Segmentation

Loading chart…

The Application segment of the Veterinary Infectious Diseases Therapeutics market refers to the various uses of therapeutics in treating infectious diseases in animals. This segment is crucial in understanding the Veterinary Infectious Diseases Therapeutics segmentation and its impact on the overall market size. The application segment is further divided into subtypes, including treatment of bacterial, viral, and parasitic infections, each contributing to the overall market size.

The Types segment of the Veterinary Infectious Diseases Therapeutics market encompasses the different types of therapeutics used to treat infectious diseases in animals. This segment is vital in understanding the market taxonomy of the Veterinary Infectious Diseases Therapeutics market. The types segment is further divided into subtypes, including antibacterial, antiviral, and antiparasitic therapeutics, each playing a significant role in the overall market size and growth.

Veterinary Infectious Diseases Therapeutics Segmentation Breakdown14 items

Application

Swine

Chicken

Dog

Cat

Cow

Horse

Other

Types

Antibiotics

Antiviral

Antifungal

Amebicides

Anthelmintics

Regional Insights

Loading chart…

The Veterinary Infectious Diseases Therapeutics market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 35% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of advanced therapeutics, favorable policies, and significant investments in the veterinary healthcare sector.

Key drivers for North America include a mature ecosystem, high demographics of pet ownership, and a well-established infrastructure for veterinary care. In Europe, factors such as stringent policies and regulations, coupled with a high level of adoption of innovative therapeutics, are expected to drive growth. Asia Pacific's growth can be attributed to a large and growing animal population, increasing investments in veterinary healthcare, and rising awareness about animal health.

Latin America and Middle East & Africa are also expected to contribute to the regional forecast, albeit at a slower pace. In Latin America, growing demand for veterinary services and increasing adoption of therapeutics are expected to drive growth. In Middle East & Africa, factors such as government initiatives to improve animal health and a rising ecosystem of veterinary care are anticipated to contribute to market growth.

Competitive Landscape

The Veterinary Infectious Diseases Therapeutics market is moderately consolidated, driven by a mix of global players and local/regional companies. The Veterinary Infectious Diseases Therapeutics competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals to maintain their market position, while local companies rely on distribution networks and pricing strategies to compete.

Companies in the market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To address these challenges, companies focus on technology, service models, channel strength, customization, and cost advantages to differentiate themselves. The following companies have notable strategies:

Elanco Animal Health: regional expansion

Merck: innovation pipeline

Pfizer Animal Health: premium pricing

Boehringer Ingelheim Vetmedica: vertical integration

Virbac: local manufacturing

Ceva Sante Animale: OEM tie-ups

Key Veterinary Infectious Diseases Therapeutics Companies9 items

Elanco Animal Health

Merck

Pfizer Animal Health

Boehringer Ingelheim Vetmedica

Virbac

Ceva Sante Animale

Novartis Animal Health

Dechra Animal Health

Sanofi

Market Ecosystem

The Veterinary Infectious Diseases Therapeutics ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to midstream integrators and downstream channels, ultimately serving end users. Value is created and captured through the development, manufacturing, and distribution of therapeutics, as well as the provision of related services. Understanding the Veterinary Infectious Diseases Therapeutics ecosystem is crucial for identifying opportunities and challenges in this market.

Raw material suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce therapeutics

Technology providers — develop innovative formulations

Distributors / channel partners — deliver products to end users

Service providers / after-sales — offer support and guidance

End users / buyers — veterinary clinics and animal owners

Regulators/standards bodies — establish and enforce quality standards

The flow of value in the Veterinary Infectious Diseases Therapeutics ecosystem is influenced by various control points, including regulatory approvals and industry standards. Dependency risks, such as input constraints and approval timelines, can impact the availability of therapeutics. Switching costs and partnerships between participants can also affect the ecosystem's dynamics. Furthermore, regional differences in regulations, disease prevalence, and animal healthcare infrastructure can lead to variations in the ecosystem across different regions, highlighting the need for a nuanced value chain analysis to understand these complexities.

Recent Industry Insights

The Veterinary Infectious Diseases Therapeutics market has witnessed significant developments over the last 12-18 months, shaping the industry trends. Recent partnerships, such as the collaboration between major pharmaceutical companies and research institutions, have accelerated the development of innovative treatments. Mergers and acquisitions have also been on the rise, with companies seeking to expand their product portfolios and strengthen their market presence. Furthermore, several product launches have taken place, introducing new and improved therapeutics to the market.

These developments are reflective of the broader Veterinary Infectious Diseases Therapeutics industry trends, which are driven by the growing demand for effective and sustainable treatments. Regulatory changes, such as updated guidelines for the approval of veterinary therapeutics, have also played a crucial role in shaping the market. Additionally, there has been a notable shift in consumer trends, with pet owners increasingly seeking advanced and specialized care for their animals, driving the demand for innovative treatments and therapies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Veterinary Infectious Diseases Therapeutics market outlook. The market exhibits a moderate level of attractiveness, driven by increasing pet ownership and the rising prevalence of infectious diseases in animals. The competitive intensity is high, with several established players and new entrants vying for market share.

The long-term outlook for the market is promising, with opportunities for growth in emerging markets and the development of innovative therapeutics. The innovation landscape is characterized by advancements in vaccine technology and antimicrobial therapy. However, the demand-supply balance is a concern, with risks of supply chain disruptions and regulatory challenges. Key risk factors include antimicrobial resistance and zoonotic diseases, which can impact market growth.

12 items

1. Executive Summary

2. Veterinary Infectious Diseases Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Veterinary Infectious Diseases Therapeutics Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Veterinary Infectious Diseases Therapeutics Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Veterinary Infectious Diseases Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Veterinary Infectious Diseases Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Veterinary Infectious Diseases Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Veterinary Infectious Diseases Therapeutics Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Veterinary Infectious Diseases Therapeutics Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Veterinary Infectious Diseases Therapeutics Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Veterinary Infectious Diseases Therapeutics Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Veterinary Infectious Diseases Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Veterinary Infectious Diseases Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Veterinary Infectious Diseases Therapeutics Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Veterinary Infectious Diseases Therapeutics Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Veterinary Infectious Diseases Therapeutics Market Competition by Key Manufacturers

9.1. Global Veterinary Infectious Diseases Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Veterinary Infectious Diseases Therapeutics: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Elanco Animal Health

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merck

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Pfizer Animal Health

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Boehringer Ingelheim Vetmedica

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Virbac

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Ceva Sante Animale

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Novartis Animal Health

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Dechra Animal Health

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Sanofi

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Veterinary Infectious Diseases Therapeutics Market

Figure 4: Global Veterinary Infectious Diseases Therapeutics Market: Drivers

Figure 5: Global Veterinary Infectious Diseases Therapeutics Market: Challenges

Figure 6: Global Veterinary Infectious Diseases Therapeutics Market: Trends

Figure 7: Global Veterinary Infectious Diseases Therapeutics Market: Opportunity

Figure 8: Global Veterinary Infectious Diseases Therapeutics Market: Restraint

Figure 9: Global Veterinary Infectious Diseases Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Veterinary Infectious Diseases Therapeutics Market Value (USD Million) By Region

Figure 19: Global Veterinary Infectious Diseases Therapeutics Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Veterinary Infectious Diseases Therapeutics Market Value (USD Million) By Region

Figure 27: Global Veterinary Infectious Diseases Therapeutics Market Share (%) By: Regions (2032)

Figure 28: Global Veterinary Infectious Diseases Therapeutics Market Volume (K) By Region

Figure 29: Global Veterinary Infectious Diseases Therapeutics Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Veterinary Infectious Diseases Therapeutics Market Value (USD Million) By Region

Figure 37: Global Veterinary Infectious Diseases Therapeutics Market Share (%) By: Regions (2032)

Figure 38: Global Veterinary Infectious Diseases Therapeutics Market Volume (K) By Region

Figure 39: Global Veterinary Infectious Diseases Therapeutics Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global Veterinary Infectious Diseases Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Veterinary Infectious Diseases Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Veterinary Infectious Diseases Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Veterinary Infectious Diseases Therapeutics Market Value (USD Million) By Region

Table 14: Global Veterinary Infectious Diseases Therapeutics Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Veterinary Infectious Diseases Therapeutics Market Volume (K) By Region

Table 31: Global Veterinary Infectious Diseases Therapeutics Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Veterinary Infectious Diseases Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Veterinary Infectious Diseases Therapeutics Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Veterinary Infectious Diseases Therapeutics Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Elanco Animal Health Basic Information And Sales Area

Table 52: Elanco Animal Health. Products Portfolio

Table 53: Merck Basic Information And Sales Area

Table 54: Merck. Products Portfolio

Table 55: Pfizer Animal Health Basic Information And Sales Area

Table 56: Pfizer Animal Health. Products Portfolio

Table 57: Boehringer Ingelheim Vetmedica Basic Information And Sales Area

Table 58: Boehringer Ingelheim Vetmedica. Products Portfolio

Table 59: Virbac Basic Information And Sales Area

Table 60: Virbac. Products Portfolio

Table 61: Ceva Sante Animale Basic Information And Sales Area

Table 62: Ceva Sante Animale. Products Portfolio

Table 63: Novartis Animal Health Basic Information And Sales Area

Table 64: Novartis Animal Health. Products Portfolio

Table 65: Dechra Animal Health Basic Information And Sales Area

Table 66: Dechra Animal Health. Products Portfolio

Table 67: Sanofi Basic Information And Sales Area

Table 68: Sanofi. Products Portfolio

Table 69: Global Market Value (USD Million) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Value (USD Million) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Market Volume (K) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Volume (K) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global Veterinary Infectious Diseases Therapeutics Market Value (USD Million) By Region

Table 78: Global Veterinary Infectious Diseases Therapeutics Market Share (%) By Region (2025-2032)

Table 79: North America Market Value (USD Million) (2025-2032) By Country

Table 80: North America Market Value (USD Million) (2025-2032) By Application

Table 81: North America Market Value (USD Million) (2025-2032) By Types

Table 82: Europe Market Value (USD Million) (2025-2032) By Country

Table 83: Europe Market Value (USD Million) (2025-2032) By Application

Table 84: Europe Market Value (USD Million) (2025-2032) By Types

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 88: South America Market Value (USD Million) (2025-2032) By Country

Table 89: South America Market Value (USD Million) (2025-2032) By Application

Table 90: South America Market Value (USD Million) (2025-2032) By Types

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 94: Global Veterinary Infectious Diseases Therapeutics Market Volume (K) By Region

Table 95: Global Veterinary Infectious Diseases Therapeutics Market Share (%) By Region (2025-2032)

Table 96: North America Market Volume (K) (2025-2032) By Country

Table 97: North America Market Volume (K) (2025-2032) By Application

Table 98: North America Market Volume (K) (2025-2032) By Types

Table 99: Europe Market Volume (K) (2025-2032) By Country

Table 100: Europe Market Volume (K) (2025-2032) By Application

Table 101: Europe Market Volume (K) (2025-2032) By Types

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 103: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 105: South America Market Volume (K) (2025-2032) By Country

Table 106: South America Market Volume (K) (2025-2032) By Application

Table 107: South America Market Volume (K) (2025-2032) By Types

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 109: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Veterinary Infectious Diseases Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	21.88 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elanco Animal Health; Merck; Pfizer Animal Health; Boehringer Ingelheim Vetmedica; Virbac; Ceva Sante Animale; Novartis Animal Health; Dechra Animal Health; Sanofi
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options